At a glance
- Originator Eli Lilly and Company
- Class Osteoporosis therapies
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 06 Jun 2001 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 27 May 1998 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)